Pfizer's Lorbrena (lorlatinib) Receives FDA Approval for Patients with 1L ALK- Positive Metastatic NSCLC
Shots:
- The approval is based on P-I/II (B7461001) study assessing Lorbrena (100mg- qd) in 215 patients with ALK-positive metastatic NSCLC- who were treated with one or more ALK TKIs
- The P-I/II (B7461001) study resulted in ORR (48%) with intracranial response rate 60% with serious AEs 32% out of 295 patients
- Lorbrena (lorlatinib) is a third-generation anaplastic lymphoma kinase (ALK) TKI indicated for patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC and is currently approved in Japan for ALK fusion gene-positive unresectable advanced and/or recurrent NSCLC with resistance or intolerance to ALK TKI
Ref: Pfizer | Image: Pharma News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com